The European Health and Digital Executive Agency (HaDEA) with the support of the European Commission organizes an info session to present three HERA’s public procurement calls […]
Join the inaugural Rare Conversations Conference aimed at facilitating essential discussion on the future of the rare disease and OMP ecosystem involving leading experts.The event will […]
The existence of messenger(m) RNA was hypothesized early in the days of DNA breakthroughs in the 1960s, and research from the 1990s started to reveal its potential as a therapeutic tool.
The Innovative Health Initiative (IHI) aims to build on the successes of the Innovative Medicines ...
Managing uncertainties in rare disease innovation Joins us for the new episode of Rare Conversations 2022! The second episode of Rare Conversations 2022 will build on […]
Healthcare Biotechnology has the potential to transform how healthcare is delivered to patients, both in terms of innovative treatments, but also via use of innovative prevention, […]
EuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific, regulatory, and policy issues between patient organisations and the biopharmaceutical industry. […]
Rare Disease Day takes place on February 28th across the globe to raise awareness among policymakers and the public about rare diseases and their impact on patient's lives and their families...
The development of therapies (OMPs) for rare diseases comes with distinct challenges, including patient recruitment, setting meaningful clinical endpoints, manufacturing and supply and finding the regulatory and market pathway to ensure patients can access therapy.
From the ongoing revision of the EU pharmaceutical legislation package and addressing critical supply issues to the impact of the recent Medical Device Regulation transition period extension, the challenges in EU healthcare and pharmaceutical policy are ever-evolving.
In April 2023, the European Commission published new legislative proposals to revise the EU’s long-standing pharmaceutical legislation and ensure it can meet the challenges of the 21st century. The revision will redefine the regulatory framework for medicines and have a significant impact on the global innovation ecosystem.
Held annually since 2004, the TOPRA Symposium is Europe’s premier conference for healthcare regulatory affairs. With dedicated programme streams for human medicines, medical devices and IVDs, and veterinary medicines, the Symposium is the must-attend event in the regulatory affairs calendar.
